Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Revenue of Pyxis Oncology, Inc. (PYXS)
Revenue in 2023 (TTM): $
According to Pyxis Oncology, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Pyxis Oncology, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-2,000,000 | $-78,493,000 | $-73,790,000 | $-73,790,000 |
| 2022 | $ | $-1,836,000 | $-122,772,000 | $-120,717,000 | $-117,953,000 |
| 2021 | $ | $-1,251,000 | $-69,070,000 | $-75,975,000 | $-81,536,000 |
| 2020 | $ | $-444,000 | $-12,425,000 | $-12,828,000 | $-12,762,000 |
| 2019 | $ | $ | $ | $-2,772,000 | $-2,665,000 |